Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 292 Prednisone 240 enzalutamide 193 Leuprolide 185 Radiotherapy 179 Abiraterone Acetate 169 Magnetic Resonance Spectroscopy 163 bicalutamide 141 Goserelin 138 Androgen Antagonists 121 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 92 gallium 68 PSMA-11 81 abiraterone 81 Specimen Handling 73 darolutamide 65 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 63 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 54 cabazitaxel 52 Standard of Care 51 Radiotherapy, Intensity-Modulated 51 Zoledronic Acid 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × dynorphin-converting endopeptidase × Clear all

NCT07583160 2026-05-13

YS247

Changhai Hospital

Phase 1 Enrolling by invitation

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡